4598 — Delta-Fly Pharma Income Statement
0.000.00%
Annual income statement for Delta-Fly Pharma, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 100 | 300 | 300 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,646 | 1,152 | 1,261 | 1,316 | 1,403 |
Operating Profit | -1,546 | -852 | -961 | -1,316 | -1,403 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1,552 | -859 | -964 | -1,326 | -1,427 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1,556 | -863 | -967 | -1,329 | -1,429 |
Net Income Before Extraordinary Items | |||||
Net Income | -1,556 | -863 | -967 | -1,329 | -1,429 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1,556 | -863 | -967 | -1,329 | -1,429 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -348 | -187 | -179 | -235 | -199 |
Dividends per Share |